The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Acyl-coenzyme A:diacylglycerol transferase (DGAT), fatty acid synthetase (FAS), and LPL are three enzymes important in adipose tissue triglyceride accumulation. To study the relationship of DGAT1, FAS, and LPL with insulin, we examined adipose mRNA expression of these genes in subjects with a wide range of insulin sensitivity (SI). DGAT1 and FAS (but not LPL) expression were strongly correlated with SI. In addition, the expression of DGAT1 and FAS (but not LPL) were higher in normal glucose-tolerant subjects compared with subjects with impaired glucose tolerance (IGT) (P < 0.005). To study the effects of insulin sensitizers, subjects with IGT were treated with pioglitazone or metformin for 10 weeks, and lipogenic enzymes were measured in adipose tissue. After pioglitazone treatment, DGAT1 expression was increased by 33 +/- 10% (P < 0.05) and FAS expression increased by 63 +/- 8% (P < 0.05); however, LPL expression was not altered. DGAT1, FAS, and LPL mRNA expression were not significantly changed after metformin treatment. The treatment of mice with rosiglitazone also resulted in an increase in adipose expression of DGAT1 by 2- to 3-fold, as did the treatment of 3T3 F442A adipocytes in vitro with thiazolidinediones. These data support a more global concept suggesting that adipose lipid storage functions to prevent peripheral lipotoxicity.
Ranganathan
Gouri
G
Central Arkansas Veterans HealthCare System, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. ranganathangouri@uams.edu
Unal
Resat
R
Pokrovskaya
Irina
I
Yao-Borengasser
Aiwei
A
Phanavanh
Bounleut
B
Lecka-Czernik
Beata
B
Rasouli
Neda
N
Kern
Philip A
PA
D017667:Adipocytes / Q000378:metabolism; D000273:Adipose Tissue / Q000201:enzymology*; D000328:Adult; D000368:Aged; D000818:Animals; D051048:Diacylglycerol O-Acyltransferase / Q000378:metabolism / Q000502:physiology*; D064429:Fatty Acid Synthases / Q000378:metabolism / Q000502:physiology*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D008071:Lipoprotein Lipase / Q000378:metabolism / Q000502:physiology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; C494881:DGAT1 protein, human; C494882:Dgat1 protein, mouse; D051048:Diacylglycerol O-Acyltransferase; D064429:Fatty Acid Synthases; D008071:Lipoprotein Lipase; D000077205:Pioglitazone